Ontario Expands Patient Access to Chronic Hepatitis C Therapies on Public Drug Plan

As of February 28, 2018, all eligible ODB recipients will have greater access to treatment, regardless of the severity of disease (fibrosis level), to achieve a cure and improve their quality of life. Patients with chronic hepatitis C will no longer have to wait for their disease to progress before starting treatment. ODB has expanded their criteria for patients with Hepatitis C to include fibrosis stages F0 and F1 to the current criteria covering F2, F3 and F4 already. In addition to expanding the fibrosis score criteria, the ODB has also eliminated the co-morbidity factor from their listing.

We would also like to notify you that effective February 28, 2018, ODB has added Vosevi to their provincial listing for patients with Hepatitis C.

“Canada has committed to eliminating hepatitis C by 2030, and to accomplish this goal we need to significantly increase treatment rates,” said Dr. Morris Sherman, Chairperson, Canadian Liver Foundation and hepatologist at Toronto General Hospital.

For more information on the expanded access for hepatitis C therapies and VOSEVI listing: http://www.health.gov.on.ca/en/pro/programs/drugs/formulary43/summary_edition43_20180221.pdf

Liver Care Canada
About the author